Search research articles
Contact Us
Filters
Showing results (71-80 of 1,922) with videos related to
Page
of 193
Sort By:
Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology
|
October 15, 2011
TOFT better explains experimental results in cancer research than SMT (comment on DOI 10.1002/bies.201100025 and DOI 10.1002/bies.201100022)
Stuart G Baker
Biometrics
|
December 17, 2013
Letter to the editor: "Comment on Hubbard and Miglioretti (2013), consider also a selection model for the cumulative risk of false positive screening tests"
Stuart G Baker
Pharmacology Research & Perspectives
|
January 4, 2026
Comparing the Molecular Pharmacological Properties of Existing β-Blockers to Determine the Theoretically Most "Ideal" Anti-Cancer β-Blocker
Jillian G Baker
Carcinogenesis
|
June 15, 2021
The case for a cancer paradox initiative
Stuart G Baker
Statistics in Medicine
|
August 9, 2019
Maximum likelihood estimation with missing outcomes: From simplicity to complexity
Stuart G Baker
Clinical Trials (London, England)
|
May 22, 2014
Principal stratification: All-or-none versus partial compliance
Stuart G Baker
Biometrics
|
September 28, 2012
Comment on Nie et al. (2011), biometrics, early view
Stuart G Baker
CA: a Cancer Journal for Clinicians
|
March 1, 1972
Evaluating new antineoplastic agents
C G Baker
Annals of Internal Medicine
|
April 21, 2018
Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials
Stuart G Baker
Statistics in Medicine
|
December 14, 2020
Modeling the mean time to interval cancer after negative results of periodic cancer screening
Stuart G Baker
Page
of 193
Search research articles
Search
Showing results (71-80 of 1,922) with videos related to
Sort By:
Page
of 193
Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology
|
October 15, 2011
TOFT better explains experimental results in cancer research than SMT (comment on DOI 10.1002/bies.201100025 and DOI 10.1002/bies.201100022)
Stuart G Baker
Biometrics
|
December 17, 2013
Letter to the editor: "Comment on Hubbard and Miglioretti (2013), consider also a selection model for the cumulative risk of false positive screening tests"
Stuart G Baker
Pharmacology Research & Perspectives
|
January 4, 2026
Comparing the Molecular Pharmacological Properties of Existing β-Blockers to Determine the Theoretically Most "Ideal" Anti-Cancer β-Blocker
Jillian G Baker
Carcinogenesis
|
June 15, 2021
The case for a cancer paradox initiative
Stuart G Baker
Statistics in Medicine
|
August 9, 2019
Maximum likelihood estimation with missing outcomes: From simplicity to complexity
Stuart G Baker
Clinical Trials (London, England)
|
May 22, 2014
Principal stratification: All-or-none versus partial compliance
Stuart G Baker
Biometrics
|
September 28, 2012
Comment on Nie et al. (2011), biometrics, early view
Stuart G Baker
CA: a Cancer Journal for Clinicians
|
March 1, 1972
Evaluating new antineoplastic agents
C G Baker
Annals of Internal Medicine
|
April 21, 2018
Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials
Stuart G Baker
Statistics in Medicine
|
December 14, 2020
Modeling the mean time to interval cancer after negative results of periodic cancer screening
Stuart G Baker
Page
of 193